Ten post jest także dostępny w języku: polski
Thanks to the newly opened research and development laboratory, OncoArendi Therapeutics will be able to increase the scope of its research work in the field of medicinal chemistry and molecular biology by conducting screening tests. This will allow the company to develop new projects with huge market potential.
A new R&D laboratory has been established in Łódź, and the space created there will enable the company to increase its research work. The expansion of work in the field of medicinal chemistry and molecular biology, including screening tests, will contribute to OncoArendi‘s development strategy. Research conducted in the new facility will range from structure analysis of potential therapeutic targets to synthesis of advanced molecules, potential drugs that will be tested in an in-vitro testing cycle. They will then undergo further stages of research, such as preclinical and clinical development phases.
According to OncoArendi’s CEO Marcin Szumowski, the new investment will allow the company to develop breakthrough drugs. Thanks to the modern infrastructure, the company will be able to explore new strategic research areas, including the platform for discovering drugs that modify RNA function. As Marcin Szumowski adds, the new laboratory will be an opportunity for the company to expand the scope of research and increase the number of developed projects, which have high market potential.
OncoArendi Therapeutics is a biotechnology company that specialises in the development of drugs used in the treatment of respiratory diseases and cancer. The company has been present on the main market of the Warsaw Stock Exchange since April 2018 and its last year’s consolidated revenues amounted to PLN 125m.